As of 2025-12-26, the EV/EBITDA ratio of Anika Therapeutics Inc (ANIK) is -14.99. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Anika's latest enterprise value is 83.53 mil USD. Anika's TTM EBITDA according to its financial statements is -5.57 mil USD. Dividing these 2 quantities gives us the above Anika EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 14.3x - 15.5x | 15.3x |
| Forward P/E multiples | 23.1x - 24.2x | 23.8x |
| Fair Price | (1.84) - 9.39 | 3.54 |
| Upside | -119.4% - -1.0% | -62.7% |
| Date | EV/EBITDA |
| 2025-12-23 | -14.76 |
| 2025-12-22 | -14.84 |
| 2025-12-19 | -15.23 |
| 2025-12-18 | -15.18 |
| 2025-12-17 | -14.87 |
| 2025-12-16 | -15.07 |
| 2025-12-15 | -15.23 |
| 2025-12-12 | -15.20 |
| 2025-12-11 | -15.02 |
| 2025-12-10 | -15.41 |
| 2025-12-09 | -15.10 |
| 2025-12-08 | -15.38 |
| 2025-12-05 | -15.31 |
| 2025-12-04 | -15.02 |
| 2025-12-03 | -14.97 |
| 2025-12-02 | -14.87 |
| 2025-12-01 | -15.72 |
| 2025-11-28 | -16.03 |
| 2025-11-26 | -15.77 |
| 2025-11-25 | -16.29 |
| 2025-11-24 | -16.00 |
| 2025-11-21 | -16.03 |
| 2025-11-20 | -14.53 |
| 2025-11-19 | -15.10 |
| 2025-11-18 | -15.49 |
| 2025-11-17 | -15.43 |
| 2025-11-14 | -16.31 |
| 2025-11-13 | -16.60 |
| 2025-11-12 | -16.60 |
| 2025-11-11 | -16.68 |
| 2025-11-10 | -16.52 |
| 2025-11-07 | -15.95 |
| 2025-11-06 | -15.69 |
| 2025-11-05 | -15.95 |
| 2025-11-04 | -15.38 |
| 2025-11-03 | -15.87 |
| 2025-10-31 | -15.69 |
| 2025-10-30 | -15.77 |
| 2025-10-29 | -15.51 |
| 2025-10-28 | -15.67 |
| 2025-10-27 | -15.56 |
| 2025-10-24 | -16.37 |
| 2025-10-23 | -15.43 |
| 2025-10-22 | -15.25 |
| 2025-10-21 | -15.77 |
| 2025-10-20 | -15.43 |
| 2025-10-17 | -14.19 |
| 2025-10-16 | -13.99 |
| 2025-10-15 | -13.99 |
| 2025-10-14 | -14.14 |